Skip to content
Axcess News – Lifestyle
Author:
FibroBiologics, Inc.
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 11, 2026
FibroBiologics CEO Issues Letter to Shareholders
May 5, 2026
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 4, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 4, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
April 30, 2026
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
April 30, 2026
VIRGINIA NATIONAL BANKSHARES CORPORATION ANNOUNCES 2026 FIRST QUARTER EARNINGS AND QUARTERLY DIVIDEND
April 24, 2026
FibroBiologics Compliant with All Nasdaq Listing Requirements
April 20, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
March 25, 2026
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
March 5, 2026
←
Previous Page
1
2
3